重組人干擾素 1 b霧化吸入治療小兒反復(fù)呼吸道感染6 0例臨床觀察

申慧麗

(河南省開封市第二人民醫(yī)院，河南 開封 475002）

重組人干擾素 1 b霧化吸入治療小兒反復(fù)呼吸道感染6 0例臨床觀察

申慧麗

(河南省開封市第二人民醫(yī)院，河南 開封 475002）

目的分析重組人干擾素 1b霧化吸入治療小兒反復(fù)呼吸道感染的臨床價值。方法 選取醫(yī)院2014年10月至2016年10月收治的反復(fù)呼吸道感染患兒120例，隨機分為試驗組和對照組，各60例。對照組患兒給予止咳、平喘、退熱、抗感染等常規(guī)治療，試驗組患兒在此基礎(chǔ)上加用重組人干擾素 1b霧化吸入治療。結(jié)果 試驗組總有效率為96．67%，明顯高于對照組的85．00%（P＜0．05）；試驗組治療后的CD4+及CD4+／CD8+高于對照組，CD8+低于對照組，組間對比有顯著性差異（P＜0．05）。結(jié)論 重組人干擾素 1b霧化吸入治療小兒反復(fù)呼吸道感染，能盡早改善患兒的臨床表現(xiàn)，提高免疫功能，值得臨床推廣。

小兒；反復(fù)呼吸道感染；重組人干擾素 1b；免疫功能；臨床療效

Abstract：Objective To analyze the clinical value of aerosol inhalation of recombinant human interferonα1b in the treatment of children with recurrent respiratory tract infection（RRTI）．M ethods Totally 120 children with RRTI treated in our hospital from October2014 to October 2016 were selected and random ly divided into the experimental group and the control group，60 cases in each group.The control group was given conventional treatment of relieving cough，relieving asthma，reducing fever and anti－infection，on this basis，the experimental group was additionally treated with aerosol inhalation of recombinant human interferonα1b.Results The total effective rate of the experimental group was 96.67%，which was significantly higher than 85.00% of the control group（P＜0.05）.After treatment，CD4+and CD4+／CD8+in the experimental group were significantly higher than those in the control group，while CD8+was significantly lower than that in the control group（P＜0.05）.Conclusion Aerosol inhalation of recombinant human interferonα1b in the treatment of children with RRTI can improve the clinical manifestation and the immune function of the children as soon as possible，it is worthy of clinical promotion.

Key words：children；recurrent respiratory tract infection；recombinant human interferonα1b；immune function；clinical effect

反復(fù)呼吸道感染（RRTI）是指兒童1年內(nèi)上、下呼吸道感染次數(shù)超過10次的一種呼吸道疾病[1]，尤其在2～6歲兒童中患病率較高。研究表明，小兒RRTI在兒科疾病中約占20%[2]。該病發(fā)病機制較為復(fù)雜，臨床認為主要與缺乏維生素、免疫功能低下、生活環(huán)境、喂養(yǎng)不當?shù)纫蛩叵嚓P(guān)。患兒臨床癥狀包括打噴嚏、咽喉腫痛、鼻塞、發(fā)熱等，全年均可發(fā)病，其中冬、春季患病率高，嚴重時可導(dǎo)致眼部、口腔、頸部淋巴結(jié)等部位出現(xiàn)不適癥狀，若病情進一步進展，則會誘發(fā)多種并發(fā)癥，如肺炎、支氣管炎等[3－4]。目前，臨床大多予以止咳化痰、抗病毒等常規(guī)對癥治療，雖能暫時控制病情，但總體療效不理想?！?br>